148 related articles for article (PubMed ID: 23150440)
1. Identification of small molecules affecting p53-MDM2/MDMX interaction by fluorescence polarization.
Zhang Q; Lu H
Methods Mol Biol; 2013; 962():95-111. PubMed ID: 23150440
[TBL] [Abstract][Full Text] [Related]
2. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
[TBL] [Abstract][Full Text] [Related]
3. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
Carotti A; Macchiarulo A; Giacchè N; Pellicciari R
Proteins; 2009 Nov; 77(3):524-35. PubMed ID: 19507240
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction.
Zhang R; Mayhood T; Lipari P; Wang Y; Durkin J; Syto R; Gesell J; McNemar C; Windsor W
Anal Biochem; 2004 Aug; 331(1):138-46. PubMed ID: 15246006
[TBL] [Abstract][Full Text] [Related]
6. Autoinhibition of MDMX by intramolecular p53 mimicry.
Chen L; Borcherds W; Wu S; Becker A; Schonbrunn E; Daughdrill GW; Chen J
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4624-9. PubMed ID: 25825738
[TBL] [Abstract][Full Text] [Related]
7. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
[TBL] [Abstract][Full Text] [Related]
8. A site-directed mutagenesis study of the MdmX RING domain.
Egorova O; Mis M; Sheng Y
Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
[TBL] [Abstract][Full Text] [Related]
9. Structural Adaptation of Secondary p53 Binding Sites on MDM2 and MDMX.
Higbee PS; Dayhoff GW; Anbanandam A; Varma S; Daughdrill G
J Mol Biol; 2024 Jul; 436(13):168626. PubMed ID: 38810774
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis for the inhibition of p53 by Mdmx.
Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
[TBL] [Abstract][Full Text] [Related]
11. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
12. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73.
Zdzalik M; Pustelny K; Kedracka-Krok S; Huben K; Pecak A; Wladyka B; Jankowski S; Dubin A; Potempa J; Dubin G
Cell Cycle; 2010 Nov; 9(22):4584-91. PubMed ID: 21088494
[TBL] [Abstract][Full Text] [Related]
13. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization.
Graves B; Thompson T; Xia M; Janson C; Lukacs C; Deo D; Di Lello P; Fry D; Garvie C; Huang KS; Gao L; Tovar C; Lovey A; Wanner J; Vassilev LT
Proc Natl Acad Sci U S A; 2012 Jul; 109(29):11788-93. PubMed ID: 22745160
[TBL] [Abstract][Full Text] [Related]
14. Non-naturally Occurring Helical Molecules Can Interfere with p53-MDM2 and p53-MDMX Protein-Protein Interactions.
Su A; Wang S; Sada A; Otani Y; Zhai L; Liu X; Sayama M; Ohki R; Ohwada T
Chem Pharm Bull (Tokyo); 2019; 67(10):1139-1143. PubMed ID: 31582633
[TBL] [Abstract][Full Text] [Related]
15. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.
Zaytsev A; Dodd B; Magnani M; Ghiron C; Golding BT; Griffin RJ; Liu J; Lu X; Micco I; Newell DR; Padova A; Robertson G; Lunec J; Hardcastle IR
Chem Biol Drug Des; 2015 Aug; 86(2):180-9. PubMed ID: 25388787
[TBL] [Abstract][Full Text] [Related]
16. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
[TBL] [Abstract][Full Text] [Related]
17. Abnormal MDMX degradation in tumor cells due to ARF deficiency.
Li X; Gilkes D; Li B; Cheng Q; Pernazza D; Lawrence H; Lawrence N; Chen J
Oncogene; 2012 Aug; 31(32):3721-32. PubMed ID: 22120712
[TBL] [Abstract][Full Text] [Related]
18. Targeting of p53 and its homolog p73 by protoporphyrin IX.
Sznarkowska A; Maleńczyk K; Kadziński L; Bielawski KP; Banecki B; Zawacka-Pankau J
FEBS Lett; 2011 Jan; 585(1):255-60. PubMed ID: 21146529
[TBL] [Abstract][Full Text] [Related]
19. Beta-peptides with improved affinity for hDM2 and hDMX.
Harker EA; Daniels DS; Guarracino DA; Schepartz A
Bioorg Med Chem; 2009 Mar; 17(5):2038-46. PubMed ID: 19211253
[TBL] [Abstract][Full Text] [Related]
20. Regulation of p53: a collaboration between Mdm2 and Mdmx.
Pei D; Zhang Y; Zheng J
Oncotarget; 2012 Mar; 3(3):228-35. PubMed ID: 22410433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]